The short answer
Pancreatin preparations covered by the label may reduce miglitol’s effect and should not be taken at the same time. The label does not provide a proven number of hours that makes the combination effective.
What this answer covers
Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters.
- Supplement or preparation
- Pancreatin
- Medication ingredient
- miglitol
The exact label names this product
Miglitol’s label specifically warns that digestive-enzyme preparations containing carbohydrate-splitting enzymes such as pancreatin may reduce its effect and should not be taken concomitantly.
Effectiveness is not the same as blood absorption
Miglitol works by delaying carbohydrate digestion at the intestinal surface. Its label states that systemic absorption is not responsible for the therapeutic effect. The warning therefore does not prove a particular reduction in blood levels.
The exact preparation matters
Pancreatin products contain differing digestive-enzyme activities. The label concern specifically includes carbohydrate-splitting enzymes; the product name alone cannot quantify the effect.
Resolve the schedule with the prescriber
Ask the pharmacist or prescriber to reconcile the two products with miglitol’s meal-start instructions. Do not invent a spacing interval or move miglitol away from meals on your own. Do not stop prescribed enzyme replacement without a treatment plan.
Evidence and practical considerations
Timing & monitoring
Label explicitly advises against concomitant use of the covered preparation; no tested hour-based gap or universal long-term avoidance rule.
- Exact scope
- Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters. with Oral miglitol RxCUI30009 IN; local intestinal alpha-glucosidase action.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary gap, systemic-exposure inference or exact unmeasured clinical-event rate.
Factors that may matter: Preparation; Meal timing; Dose; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral miglitol
Intestinal alpha-glucosidase inhibition; systemic absorption does not contribute to therapeutic effect. Alone should not cause hypoglycemia, but insulin/sulfonylurea co-use can increase their risk. Glucose rather than sucrose treats appropriate mild-to-moderate lows. Charcoal adsorbents and carbohydrate-splitting enzymes may reduce effect and should not be taken concomitantly.
How this applies: Exact oral miglitol and its local intestinal action distinguished from other diabetes medicines.
Class and named-product precautions do not establish each herb interaction, a quantified absorption change or arbitrary spacing interval.
Research assessment: · Open full citations ↗
Absorption & effectiveness
Label supports possible reduced intestinal therapeutic effect, not quantified systemic absorption loss.
- Exact scope
- Oral pancreatin preparations with carbohydrate-splitting enzymes such as amylase; enzyme composition matters. with Oral miglitol RxCUI30009 IN; local intestinal alpha-glucosidase action.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary gap, systemic-exposure inference or exact unmeasured clinical-event rate.
Factors that may matter: Preparation; Meal timing; Dose; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral miglitol
Intestinal alpha-glucosidase inhibition; systemic absorption does not contribute to therapeutic effect. Alone should not cause hypoglycemia, but insulin/sulfonylurea co-use can increase their risk. Glucose rather than sucrose treats appropriate mild-to-moderate lows. Charcoal adsorbents and carbohydrate-splitting enzymes may reduce effect and should not be taken concomitantly.
How this applies: Exact oral miglitol and its local intestinal action distinguished from other diabetes medicines.
Class and named-product precautions do not establish each herb interaction, a quantified absorption change or arbitrary spacing interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact miglitol article distinguishing local efficacy, systemic absorption and product-specific timing. | |
| Research summary published |
Article revision: 291fbccd73d54c77
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.